Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...
The European Commission has approved Sanofi and Regeneron’s Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria.
Sanofi ( SNY) and Regeneron’s ( REGN) Dupixent has gained EU approval as the first targeted therapy in more than ten years ...
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...
Patients with chronic spontaneous urticaria who respond rapidly to omalizumab show longer treatment persistence and require ...
In September 2025, the US Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral small molecule kinase inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in ...
The MarketWatch News Department was not involved in the creation of this content. EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often ...
UNDERSTANDING what matters most to patients with chronic urticaria is vital to delivering care that truly reflects their needs and priorities. A new systematic review, encompassing 18 studies and over ...
France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...
Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback